高级检索

不同剂量重组人生长激素对小于胎龄儿矮小症患儿相关指标的影响

Effects of different doses of recombinant human growth hormone on related factors in dwarfism children who were smaller for gestational age

    摘要
  • 摘要:
      目的  探讨大剂量重组人生长激素(rhGH)与小剂量rhGH对小于胎龄儿(SGA)矮小症患儿身高标准差的增长值(△HtSDS)、生长速率(HV)、血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)的影响。
      方法  选取110例SGA矮小症患儿作为研究对象，按用药剂量的不同分为2组，各55例。小剂量组患儿每日服用0.10~0.15 IU/kg的rhGH, 大剂量组患儿每日服用0.16~0.20 IU/kg的rhGH, 对比2组的用药效果。
      结果  治疗后6、12、24个月，大剂量组的△HtSDS、HV、血清IGF-1、IGFBP-3水平均显著高于小剂量组(P < 0.05)。
      结论  大剂量rhGH应用于SGA矮小症患儿的治疗中优势明显，对患儿△HtSDS、HV、血清IGF-1、IGFBP-3的正性影响更大。

     

    Abstract:
      Objective  To investigate the effects of high-dose recombinant human growth hormone (rhGH) and low-dose rhGH on growth value of standard height deviation (△HtSDS), growth velocity (HV), serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) of dwarfism children who were smaller for gestational age (SGA).
      Methods  A total of 110 patients were selected as study subjects and were divided into two groups according to differed doses, with 55 cases per group. The patients in the low-dose group were given rhGH for 0.10~0.15 IU/kg daily, and those in the high-dose group were orally administrated rhGH for 0.16~0.20 IU/kg. The drug efficacy between the two groups was compared.
      Results  At 6, 12 and 24 months after treatment, the levels of △HtSDS, HV, blood IGF-1 and IGFBP-3 in the high dose group were higher than those in the low dose group (P < 0.05).
      Conclusion  High dose of rhGH has more obvious advantages in the treatment of SGA dwarfism children, and has more positive effects on HtSDS, HV, blood IGF-1 and IGFBP-3.

     

    • HTML全文
    • 参考文献(18)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回